REG - RUA Life Sciences - Change of Auditor

Rua Life SciencesAnnouncement

30/01/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240130:nRSd2814Ba&default-theme=true

RNS Number : 2814B  RUA Life Sciences PLC  30 January 2024

30 January 2024

 

 

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Change of Auditor

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical
device businesses focused on the exploitation of Elast-Eon™, the
world-leading long-term implantable biostable polyurethane, announces that,
following a competitive audit tender process undertaken by the Company, the
Board has approved the appointment of RSM UK LLP ("RSM") as the Group's new
external auditor. Grant Thornton UK LLP ("Grant Thornton") has resigned as the
Group's auditor.

RSM will conduct the audit of the Group's financial statements for the
financial period to 31 March 2024, and a proposal to re-appoint RSM as
auditors of the Group will be subject to shareholders' approval at the 2024
Annual General Meeting.

Grant Thornton has been the auditor for the Company since 2006, and we thank
them for their services over this time.  Grant Thornton has confirmed to the
Company that there are no matters connected with their ceasing to hold office
that need to be brought to the attention of the members or creditors of the
Company for the purposes of section 519 of the Companies Act 2006.

 

 

For further information contact:

 

RUA Life
Sciences
Tel: +44 (0)1294 317073

Bill Brown, Chairman
 

Lachlan Smith, Chief Financial Officer
 
 
 

 

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)  Tel: +44
(0)20 7220 0500

Giles Balleny / Dan Hodkinson (Corporate Finance)

Dale Bellis / Charlie Combe (Sales & ECM)

Michael Johnson (Sales)

 

About RUA Life Sciences

 

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the Group's four
trading businesses, each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by enabling medical
devices with Elast-Eon(TM), the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-Eon(TM), manufacturing a device or
component, or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

 

The Group's four business units are:

 

 RUA Contract Manufacture:  End-to-end contract developer and manufacturer of medical devices and
                            implantable fabric specialist.

 RUA Biomaterials:          Licensor of Elast-Eon(TM) polymers to the medical device industry.

 RUA Vascular:              Commercialisation of open surgical vascular grafts and patches

 RUA Structural Heart:      Development of polymeric leaflet systems for heart valves.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFLFITLTIAFIS